The Frequency of Specific KRAS Mutations, and Their Impact on Treatment Choice and Survival, in Patients With Metastatic Colorectal Cancer
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Background: Patients with metastatic colorectal cancer (mCRC) and KRAS mutations have a poor prognosis, seemingly dependent on the location of the mutation. This multicenter, retrospective, cohort study assessed the frequency and prognostic value of specific KRAS mutation codon locations in mCRC patients, and survival outcomes in relation to treatment. Materials and Methods: Data from mCRC patients treated in 10 Spanish hospitals between January 2011 and December 2015 were analyzed. The main objective was to investigate (1) the impact of KRAS mutation location on overall survival (OS), and (2) the effect of targeted treatment plus metastasectomy and primary tumor location on OS in patients with KRAS mutations. Results: The KRAS mutation location was known for 337/2002 patients. Of these, 177 patients received chemotherapy only, 155 received bevacizumab plus chemotherapy, and 5 received anti-epidermal growth factor receptor therapy plus chemotherapy; 94 patients underwent surgery. The most frequent KRAS mutation locations were G12A (33.8%), G12D (21.4%), and G12V (21.4%). Compared with other locations, patients with a G12S mutation had the shortest median OS (10.3 [95% CI, 2.5-18.0] months). OS was longer in patients who underwent surgery versus those who did not, with a trend toward prolonged survival with bevacizumab (median OS 26.7 [95% CI, 21.8-31.7] months) versus chemotherapy alone (median OS 23.2 [95% CI, 19.4-27.0] months). Conclusion: These findings confirm that KRAS mutation location may predict survival outcomes in patients with mCRC, and suggest that pre-/post-operative bevacizumab plus metastasectomy provides survival benefits in patients with KRAS mutations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In general, activating KRAS mutations in mCRC are associated with accelerated metastatic progression [67] and relatively poor outcomes with G12S mutations associated with a particularly high mortality rate [68].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [68]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
SEER Cancer Statistics Review, 1975-2003
Ries, L. A. G., Harkins, D., Krapcho, M. F., Mariotto, A. B., Miller, B., Feuer, E. J., Clegg, L. X., Eisner, M. P., Horner, M., Howlader, N., et al. (2006) · Digital Archive @ GSU · Cited by 11,774
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw235 · Cited by 3,421
De Roock, W., Piessevaux, H., De Schutter, J., Janssens, M., De Hertogh, G., Personeni, N., Biesmans, B., Van Laethem, J.-L., Peeters, M., Humblet, Y., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm496 · Cited by 827
van der Geest, L. G. M., Lam-Boer, J., Koopman, M., Verhoef, C., Elferink, M. A. G., & de Wilt, J. H. W. (2015) · Clinical & Experimental Metastasis · doi:10.1007/s10585-015-9719-0 · Cited by 530
Safiri, S., Sepanlou, S. G., Ikuta, K. S., Bisignano, C., Salimzadeh, H., Delavari, A., Ansari, R., Roshandel, G., Merat, S., Fitzmaurice, C., et al. (2019) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(19)30345-0 · Cited by 421
Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.
Neumann, J., Zeindl-Eberhart, E., Kirchner, T., & Jung, A. (2009) · Pathology - Research and Practice · doi:10.1016/j.prp.2009.07.010 · Cited by 361
Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes
Stintzing, S., Tejpar, S., Gibbs, P., Thiebach, L., & Lenz, H.-J. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.07.016 · Cited by 277
Imamura, Y., Morikawa, T., Liao, X., Lochhead, P., Kuchiba, A., Yamauchi, M., Qian, Z. R., Nishihara, R., Meyerhardt, J. A., Haigis, K. M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3210 · Cited by 249
Prognostic and Predictive Roles of KRAS Mutation in Colorectal Cancer
Arrington, A. K., Heinrich, E. L., Lee, W., Duldulao, M., Patel, S., Sanchez, J., Garcia-Aguilar, J., & Kim, J. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms131012153 · Cited by 244
Phipps, A. I., Buchanan, D. D., Makar, K. W., Win, A. K., Baron, J. A., Lindor, N. M., Potter, J. D., & Newcomb, P. A. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.118 · Cited by 238
Wong, R., Cunningham, D., Barbachano, Y., Saffery, C., Valle, J., Hickish, T., Mudan, S., Brown, G., Khan, A., Wotherspoon, A., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq714 · Cited by 206
Kekelidze, M. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i46.8502 · Cited by 176
Bylsma, L. C., Gillezeau, C., Garawin, T. A., Kelsh, M. A., Fryzek, J. P., Sangaré, L., & Lowe, K. A. (2020) · Cancer Medicine · doi:10.1002/cam4.2747 · Cited by 133
Rumpold, H. F., Niedersüß‐Beke, D., Heiler, C., Falch, D., Wundsam, H., Metz-Gercek, S., Piringer, G., & Thaler, J. (2020) · BMC Cancer · doi:10.1186/s12885-020-07656-w · Cited by 133
Li, Z.-N., Zhao, L., Yu, L.-F., & Wei, M.-J. (2020) · Gastroenterology Report · doi:10.1093/gastro/goaa022 · Cited by 104
Vera, R., González‐Flores, E., Rubio, C., Urbano, J., Camps, M. V., Ciampi-Dopazo, J. J., Rincón, J. O., Macías, V. M., Braco, M. A. G., & Artacho, G. S. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02182-z · Cited by 90
More is less—combining targeted therapies in metastatic colorectal cancer
Punt, C. J. A., & Tol, J. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.168 · Cited by 82
Fiala, O., Buchler, T., Mohelnikova-Duchonova, B., Melichar, B., Matejka, V. M., Holubec, L., Kulhankova, J., Bortlicek, Z., Bartouskova, M., Liska, V., et al. (2016) · Tumor Biology · doi:10.1007/s13277-015-4523-7 · Cited by 55
Global impact of KRAS mutation patterns in FOLFOX treated metastatic colorectal cancer
Zocche, D. M., Ramirez, C., Fontao, F. M., Costa, L. D., & Redal, M. A. (2015) · Frontiers in Genetics · doi:10.3389/fgene.2015.00116 · Cited by 50
Hackl, C., Gerken, M., Loss, M., Klinkhammer‐Schalke, M., Piso, P., & Schlitt, H. J. (2011) · International Journal of Colorectal Disease · doi:10.1007/s00384-011-1278-5 · Cited by 39
Kwak, M. S., Cha, J. M., Yoon, J. Y., Jeon, J. W., Shin, H. P., Chang, H. J., Kim, H. K., Joo, K. R., & Lee, J. I. (2017) · Medicine · doi:10.1097/md.0000000000007882 · Cited by 36
Bruera, G., Cannita, K., Giacomo, D. D., Lamy, A., Frébourg, T., Sabourin, J. C., Tosi, M., Alesse, E., Ficorella, C., & Ricevuto, E. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-59 · Cited by 25
Joharatnam‐Hogan, N., Wilson, W., Shiu, K., Fusai, G., Davidson, B. R., Hochhauser, D., Bridgewater, J. A., & Khan, K. H. (2020) · Cancers · doi:10.3390/cancers12123545 · Cited by 16
Pietrantonio, F., Cotsoglou, C., Fucà, G., Vullo, S. L., Nichetti, F., Milione, M., Coppa, J. C., Vaiani, M., Alessi, A., Prisciandaro, M., et al. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.11.004 · Cited by 13
Chibaudel, B., André, T., Tournigand, C., Louvet, C., Benetkiewicz, M., Larsen, A. K., & de Gramont, A. (2020) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2020.02.012 · Cited by 10
Jacome, A. A. D. A., Oliveira, F. A. D. S. D. S., Lino, F., & Lima, J. P. D. S. N. (2021) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2021.05.006 · Cited by 10
Cited by
Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment
Gmeiner, W. H. (2024) · Cancers · doi:10.3390/cancers16051029 · Cited by 78
Genetic, Epidemiological, Clinical, and Therapeutic Trajectories in Colon and Rectal Cancers
Capuozzo, M., Picone, C., Sabbatino, F., Santorsola, M., Caraglia, F., Iervolino, D., Sirica, R., Gualillo, O., Mauro, G. D., Castiello, R., et al. (2025) · Cancers · doi:10.3390/cancers17213438 · Cited by 28
Targeted degradation of oncogenic KRASG12V triggers antitumor immunity in lung cancer models
Li, D., Geng, K., Yuan, H., Gu, J., Kumar, S., Olson, A. T., Kuismi, C. C., Kim, H. M., Pan, Y., Sherman, F., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci174249 · Cited by 21
Rai, S. K., Du, W., Zhang, J., Yu, H., Deng, Y., & Fei, P. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1462810 · Cited by 10
Sianoya, A. C., Zuo, Y., Pagba, C. V., Jakubec, J. L., Planque, S. A., Frost, J. A., Medina, P. M. B., & Gorfe, A. A. (2026) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-25-1087 · Cited by 6
Metadata
- Authors
- Fernández Montes, A., Alonso Orduña, V., Asensio Martínez, E., Rodríguez Salas, N., Torres, E., Cacho Lavín, D., Rodríguez Alonso, R. M., Falcó, E., Oliva, J. C., Cirera, L., García Gómez, J., & Pericay, C.
- Affiliations
- Servicio de Oncología Médica, Complexo Hospitalario Universitario de Ourense , Calle Ramón Puga Noguerol, Ourense , Spain
- Servicio de Oncología Médica, Hospital Universitario Miguel Servet, Instituto de Investigacion Sanitaria de Aragon , Paseo Isabel la Católica, Zaragoza , Spain
- Servicio de Oncología Médica, Hospital General Universitario de Elche , Carrer Almazara, Elche, Alicante , Spain
- Servicio de Oncología Médica, Hospital Universitario La Paz , Paseo de la Castellana, Madrid , Spain
- Instituto de Investigación Biomédica de Málaga (ES)
- Servicio de Oncología Médica, Hospital Universitario Marqués de Valdecilla , Santander, Cantabria , Spain
- Servicio de Oncología Médica, Hospital Universitario Reina Sofía-Córdoba , Avenida Menéndez Pidal, Córdoba , Spain
- Hospital Son Llatzer (ES)
- Institute of Research and Innovation Parc Tauli (ES)
- University Hospital Mútua de Terrassa (ES)
- Corporació Sanitària Parc Taulí (ES)
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2023-05-04
- Volume
- 28
- Issue
- 10
- Pages
- e902-e909
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- PMC
- PMC10546812
- OpenAlex
- W4368342849
- Cited by
- 17
- References
- 27
- Citations by year
- 2026: 7 · 2025: 5 · 2024: 4 · 2023: 1
- FWCI
- 2.06
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- The Oncologist (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Docusalut (Conselleria de Salut i Consum del Govern de les Illes Balears) (submittedVersion, cc-by)
- Hispana (submittedVersion, cc-by)
- Funders
- Merck
- Merck KGaA
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- KRAS mutation, metastatic colorectal cancer, overall survival, bevacizumab, metastasectomy, anti-EGFR therapy, chemotherapy, prognostic factors, treatment selection
- MeSH terms
- Bevacizumab, Antineoplastic Combined Chemotherapy Protocols, Colonic Neoplasms, Humans, Mutation, Prognosis, Rectal Neoplasms, Retrospective Studies, Colorectal Neoplasms, Cohort Studies, Proto-Oncogene Proteins p21(ras)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.